AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
55.41
-1.87 (-3.26%)
Mar 6, 2026, 4:00 PM EST - Market closed
AnaptysBio Employees
AnaptysBio had 104 employees as of December 31, 2025. The number of employees decreased by 32 or -23.53% compared to the previous year.
Employees
104
Change (1Y)
-32
Growth (1Y)
-23.53%
Revenue / Employee
$2,255,798
Profits / Employee
-$127,231
Market Cap
1.59B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 952 |
| Agios Pharmaceuticals | 540 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Nuvation Bio | 291 |
| Innoviva | 159 |
| Nanobiotix | 103 |
ANAB News
- 4 days ago - Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 10 days ago - Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 4 weeks ago - Anaptys Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - Reuters
- 2 months ago - Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary - GlobeNewsWire
- 2 months ago - Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 3 months ago - Anaptys Announces Participation in December Investor Conferences - GlobeNewsWire